Key result
In a network pharmacology analysis, ilaprazole and pantoprazole shared fewer targets with clopidogrel (13.6%) compared to conventional PPIs (14.9%) and did not involve CYP2C19 as a hub gene.
Why the study?
PPIs may reduce clopidogrel potency via CYP2C19 inhibition, but the novel PPI ilaprazole differs pharmacokinetically, prompting investigation into its specific drug-drug interactions.
Do ilaprazole and pantoprazole have a lower risk of CYP2C19-mediated drug-drug interactions with clopidogrel compared to conventional proton pump inhibitors?
Do ilaprazole and pantoprazole have a lower risk of CYP2C19-mediated drug-drug interactions with clopidogrel compared to conventional proton pump inhibitors?
Absolute Event Rate: 13.6% vs 14.9%
Network pharmacology analysis suggests that ilaprazole and pantoprazole may not significantly inhibit CYP2C19, potentially lowering the risk of adverse interactions with clopidogrel compared to conventional PPIs.
May indicate lower interaction risk with ilaprazole/pantoprazole; leaves open prospective clinical validation in clopidogrel-treated patients.
BACKGROUND: Clopidogrel, an antiplatelet drug commonly used in cardiovascular disease, is metabolized by the liver mainly through CYP2C19. Concomitant use of Proton pump inhibitors along with clopidogrel may affect the potency of clopidogrel by CYP2C19 inhibition. However, a novel PPI, ilaprazole is known to differ in its pharmacokinetic features, given the potential differences between ilaprazole's interactions and their metabolism with clopidogrel. Network pharmacology investigation could be a useful tool to evaluate the drug-drug interaction between them. METHODOLOGY: The molecular structures and targets were retrieved from PubChem and SwissTargetPrediction to establish the information related to the identified drugs. The possible shared targets between the clopidogrel and PPIs were explored by a Venn analysis. Subsequently, Protein-Protein Interaction networks were established using the STRING database. Hub genes were also determined using the Cytoscape cytoHubba plugin. RESULTS AND DISCUSSION: Ilaprazole (13.6%) and pantoprazole (13.6%) were characterized by fewer targets being shared with clopidogrel compared to conventional PPIs (14.9%). Moreover, CYP2C19 was not a hub gene in ilaprazole and pantoprazole interactions, which indicated no significant CYP2C19 involvement. On the other hand, CYP2C19 functioned as a hub gene in the interactions with rabeprazole, lansoprazole, dexlansoprazole, omeprazole, and esomeprazole. As a result, patients receiving pantoprazole and ilaprazole would be at a lower risk for developing adverse cardiovascular events by maintaining the clopidogrel therapeutic effect. CONCLUSION: CYP2C19. There is a lower chance of experiencing adverse effects from an interaction between ilaprazole and clopidogrel as ilaprazole has not been linked to CYP2C19. More research is necessary to confirm these results and provide clinical guidance for patients undergoing clopidogrel and PPI combination therapy.
No takes yet. Share an insight, caveat, or question.
Ananthathandavan et al. (2025) studied Cardiovascular disease. Ilaprazole and pantoprazole vs. Conventional proton pump inhibitors was evaluated on Shared targets with clopidogrel. In a network pharmacology analysis, ilaprazole and pantoprazole shared fewer targets with clopidogrel (13.6%) compared to conventional PPIs (14.9%) and did not involve CYP2C19 as a hub gene.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: